Renaissance Capital logo

Unicycive Therapeutics Priced, Nasdaq: UNCY

Early-stage biotech developing in-licensed therapies for kidney disease.

Industry: Health Care

Latest Trade: $1.38 0.00 (0.0%)

First Day Return: +17.0%

Return from IPO: -72.4%

Industry: Health Care

We are a biotechnology company dedicated to developing treatments for certain medical conditions. Currently, two of our programs are focused on kidney disease that we believe have the potential to offer medical benefit. As we grow the Company and build our team, we intend to focus on identifying medical conditions within and outside of kidney disease. Our current development programs are focused on the development of two novel therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb and UNI 494 were initially developed by, and licensed to us from, Spectrum Pharmaceuticals (“Spectrum”) and Sphaera Pharmaceuticals, respectively. Spectrum conducted a Phase 1 clinical trial with Renazorb in 2012 prior to the grant of our license in 2018. Sphaera conceived, and performed initial characterization of, various potential pro-drug linkers, including the initial patent application, and performed some initial physiochemical characterization and preliminary animal pharmacokinetic studies. As discussed herein, during 2020 we have conducted preclinical studies with UNI 494.
more less
IPO Data
IPO File Date 05/21/2021
Offer Price $5.00
Price Range $5.00 - $6.00
Offer Shares (mm) 5.0
Deal Size ($mm) $25
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/12/2021
Offer Price $5.00
Price Range $5.00 - $6.00
Offer Shares (mm) 5.0
Deal Size ($mm) $25
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Roth Capital
Company Data
Headquarters Los Altos, CA, United States
Founded 2016
Employees 1
Website unicycive.com

Unicycive Therapeutics (UNCY) Performance